{"id":1044173,"title":"Résumé du RIEM : Inhibiteurs du SGLT2 et risque d’amputation transtibiale - IRSC","sourceCode":"cihr","sourceName":"Canadian Institutes of Health Research","language":"fr","captureDate":"2026-03-10","captureTimestamp":"2026-03-10T22:36:46.834000+00:00","jobId":8,"originalUrl":"https://cihr-irsc.gc.ca/f/53777.html","snippet":"Résumé du RIEM Inhibiteurs du SGLT2 et risque d’amputation transtibiale Étude menée par le Réseau canadien pour l’étude observationnelle des médicaments ( CNODES) Quelle est la question? Les inhibiteurs du cotransporteur sodium glucose de type 2 (SGLT2) sont une nouvelle classe…","rawSnapshotUrl":"/api/snapshots/raw/1044173","browseUrl":"https://replay.healtharchive.ca/job-8/20260310223646/https://cihr-irsc.gc.ca/f/53777.html#ha_snapshot=1044173","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}